| Jul 30 |
Countdown to Biogen (BIIB) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
|
| Jul 30 |
Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
|
| Jul 29 |
EU CHMP snubs Biogen and Eisai’s Alzheimer’s therapy Leqembi
|
| Jul 29 |
Alzheimer’s Disease: Some trials to watch over the next year
|
| Jul 29 |
What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?
|
| Jul 29 |
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
|
| Jul 29 |
Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy?
|
| Jul 29 |
Shares of Japan's Eisai tumble after EU rejects Alzheimer's drug
|
| Jul 29 |
Eisai Shares Sink on Surprise EU Rejection of Alzheimer’s Drug
|
| Jul 27 |
This Biogen Insider Increased Their Holding In The Last Year
|
